Phosphodiesterase-5 Inhibitor Attenuates Anxious Phenotypes and Movement Disorder Induced by Mild Ischemic Stroke in Rats

Yeon Hee Yu1,2*, Seong-Wook Kim3*, Juhyeon Kang1,2*, Yejin Song1,2, Hyuna Im1,2, Seo Jeong Kim1,2, Dae Young Yoo1,2, Man-Ryul Lee4, Dae-Kyoon Park1,2, Jae Sang Oh4†, Duk-Soo Kim1,2

1Department of Anatomy and 2BK21 FOUR Project, College of Medicine, Soonchunhyang University, Cheonan 31151, Republic of Korea.

3Graduate School of New Drug Discovery & Development, Chungnam National University, Daejeon, Republic of Korea.

4Soonchunhyang Institute of Medi-bio Science (SIMS), Soonchunhyang University, Cheonan 31151, Republic of Korea.

5Department of Neurosurgery, College of Medicine, Soonchunhyang University, Cheonan Hospital, Cheonan 31151, Korea, Republic of Korea.

*These authors contributed equally to this work.

Running Head: Phosphodiesterase-5 inhibitor in ischemic stroke

• Received: April 20, 2021 • Revised: November 17, 2021 • Accepted: February 3, 2022

Correspondence to:
Duk-Soo Kim, Tel: +82-41-570-2470, Fax: +82-41-574-1770, E-mail: dskim@sch.ac.kr,
ORCID: https://orcid.org/0000-0003-2956-3942;

Laboratory Investigation

https://doi.org/10.3340/jkns.2021.0101
Jae Sang Oh, Tel: +82-41-570-3653, E-mail: metatron1324@hotmail.com, ORCID:

https://orcid.org/0000-0003-4570-6769

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2022 The Korean Neurosurgical Society
Abstract

Objective: Patients with mild ischemic stroke experience various sequela and residual symptoms, such as anxious behavior and deficits in movement. Few approaches have been proved to be effective and safe therapeutic approaches for patients with mild ischemic stroke by acute stroke. Sildenafil, a phosphodiesterase-5 inhibitor (PDE5i), is a known remedy for neurodegenerative disorders and vascular dementia through its angiogenesis and neurogenesis effects. In this study, we investigated the efficacy of PDE5i in the emotional and behavioral abnormalities in rats with mild ischemic stroke.

Methods: We divided the rats into four groups as follows (n = 20, respectively): group 1, naïve; group 2, middle cerebral artery occlusion (MCAo30); group 3, MCAo30 + SIL-Pre; and group 4, MCAo30 + SIL-Post. In the case of drug administration groups, single dose of PDE5i (sildenafil citrate, 20 mg/kg) was given at 30-min before and after reperfusion of MCAo in rats. After surgery, we investigated and confirmed the therapeutic effect of sildenafil on histology, immunofluorescence, behavioral assays and neural oscillations.

Results: Sildenafil alleviated a neuronal loss and reduced the infarction volume. And results of behavior task and immunofluorescence shown possibility that anti-inflammation process and improve motor deficits sildenafil treatment after mild ischemic stroke. Furthermore, sildenafil treatment attenuated the alteration of theta-frequency rhythm in the CA1 region of the hippocampus, a known neural oscillatory marker for anxiety disorder in rodents, induced by mild ischemic stroke.

Conclusion: PDE5i as effective therapeutic agents for anxiety and movement disorders and provide robust preclinical evidence to support the development and use of PDE5i for the treatment of mild ischemic stroke residual disorders.
Key words: Infarction, Middle cerebral artery, Ischemic stroke, Phosphodiesterase 5 inhibitor, Sildenafil Citrate
Introduction

Ischemic stroke, one of the leading causes of death worldwide, is caused by interruption or significant impairment of blood supply to the brain leading to molecular and metabolic disorders such as brain injury, epileptic seizures, sensorimotor deficits, and vascular dementia. Furthermore, while the symptoms of minor stroke or transient ischemic attack (TIA) are short term and are associated with fast recovery, patients with TIA experience various sequela and residual symptoms including deficits in emotion and cognition and anxiety disorder. Especially, ischemia/reperfusion injury, which is characterized by a cascade of events leading to neuronal injury, facilitates the release of nitric oxide (NO), and the induction of programmed cell death.

Although diverse treatment methods for stroke have been developed, very few approaches have been proved to be effective and safe therapeutic approaches for patients with acute stroke. For example, thrombolysis, which aims at rehabilitating blood flow to the infarct site of the brain tissue following ischemic attack, is an effective treatment for acute ischemic stroke. In spite of its efficacy, thrombolysis treatment has several limitations, such as a comparatively short therapeutic time-window (up to 4.5h) and adverse side effects induced by hemorrhage. Thus, new therapeutic approaches for acute ischemic stroke targeting different molecular and cellular substrates are necessary.

Phosphodiesterase-5 (PDE5) is a cyclic nucleotide phosphodiesterase expressed in several brain cell types and smooth muscle cells. PDE5 activates the cyclic guanosine monophosphate (cGMP) pathway, one of the second messengers signaling, and triggers its hydrolysis to GMP. Through protein kinase G (PKG), cGMP activates downstream intracellular mechanisms, such as the cyclic adenosine monophosphate (cAMP)-response element binding protein (CREB), a cellular transcription factor, involved in cell survival and synaptic plasticity. Sildenafil, branded as Viagra®, is a selective inhibitor of cGMP-specific PDE5 with the efficacy of blocking the degradative action of PDE5 on cGMP. Furthermore,
previous imaging studies using positron emission tomography in mice indicated that sildenafil crosses the blood-brain barrier (BBB) and interact with endothelium and/or smooth muscle cells of brain vessels and PDE5 expressed in brain cells although mechanisms underlying their penetration into BBB have not yet been suggested. PDE5i have therapeutic effects in erectile dysfunction, pulmonary hypertension, modulates neurogenesis and gliosis, improves cognition deficits, and has been shown to ameliorate amyloid burden in Alzheimer’s disease mouse model. However, the therapeutic efficacy of PDE5i in anxiety disorder following mild stroke remains unclear; the prevalence of post-stroke anxiety is high and has been associated with an increased risk of incident stroke.

In this study, therefore, we characterized distinctive loss of neuronal cells, brain tissue damage, and emotional and behavioral abnormalities in rats with mild ischemic stroke. We hypothesized that the use of PDE5i is a novel therapeutic approach for the improvement of cerebral blood flow in the infarct region in the brain, and investigated the efficacy of PDE5i in emotional and behavioral abnormalities.

**Materials and methods**

**Animals**

Male Sprague-Dawley (SD) rats (8 weeks of age and 260-280 g of body weight) were used to establish a MCAo model. Rats were provided with a commercial diet and water ad libitum under controlled temperature, humidity and lighting conditions (light/dark cycle 12:12, and 22±2°C, 55±5%). All animal studies and experimental procedures were approved by the Administrative Panel on Laboratory Animal Care of Soonchunhyang University (permit No. SCH16-0024). All possible efforts were made to avoid the suffering of the rats and to minimize the number used during the experiments.

**Oclusion of the middle cerebral artery**
Focal brain ischemia was induced using a relatively non-invasive technique as described previously. Briefly, rats were anesthetized with 2% isoflurane in a mixture of oxygen and nitrous oxide gases (0.3:0.7), and body temperature was maintained at 37°C with a heating pad during surgery. The tip of a 4-0-monofilament nylon suture (Nylon suture, Medtronic PLC, Minneapolis, MN, USA) was coated with dental silicone to a thickness of 0.37±0.02 mm and a piece of the filament was coated with 0.01% (w/v) poly-L-lysine (Sigma-Aldrich, St. Luis, MO, USA). The monofilament was inserted into the left common carotid artery (CCA), and advanced from 18 mm point toward the internal carotid artery (ICA) to occlude the ostium of the middle cerebral artery (MCA). A laser Doppler probe (Millwey, Axminste, UK) was fixed on the parietal bone (1.5 mm posterior and 5 mm to the bregma point) to measure the local cortical blood flow supplied by the MCA during surgery. Successful occlusion was determined by 20% decrease to baseline in local cortical blood flow. 30-min after brain ischemia, MCA was reperfused from transient ischemia (MCAo30), and the rats recovered from anesthesia within a few minutes. Seven days after surgery, the rats were screened using behavioral tasks of examining movement disorders, such as inability to extend the contralateral forelimb and circling towards the contralateral to infarct following neurological deficits, for verifying an induction of MCAo as described previously. At designated time courses, the rats screened for the MCAo-related deficits in movement were used for anxiety-related behavioral tests, electrophysiology, and immunohistochemistry. Age-matched naïve rats were used as controls.

**Drug preparation and administration**

To evaluate whether sildenafil citrate has an effect on the improvement of diverse phenotypical sequela induced by mild ischemic stroke, PDE5i (sildenafil citrate, 20 mg/kg; Hanmi Parm, Seoul, Republic of Korea) was intraperitoneally (i.p.) administered into the rats. A single dose of PDE5i dissolved in 0.9% saline was given at 30-min before and after reperfusion of MCAo respectively, as described previously. We divided the rats into four groups as follows (n = 20,
respectively): group 1, naïve; group 2, MCAo 30; group 3, MCAo30 + SIL-Pre; and group 4, MCAo30 + SIL-Post.

**Behavioral assays**

To allow adaption to the environmental conditions of all behavioral assays, the rats were exposed to white noise for 30-min before the ongoing behavioral tests, which is created by combining sounds of the identical frequency at 60 Hz.

**Open-field test**

Behavioral assay for locomotor activity and anxiety was carried out according to the procedures described previously. The total distance moved was used as a parameter to evaluate the locomotor activity. The open-field box (60×60×40 cm; length, width, height) was placed in an isolated room without any clues. Each individual rat was placed in the open-field arena under diffusing light. The extent of their spontaneous movement in the open-field box within 30-min was recoded, and analyzed using EthoVision 3.1 software (Noldus Information Technology, Wageningen, Netherlands).

**Light-dark transition test**

Behavioral assay for anxiety was performed as described previously. The light-dark box (45×27×27 cm; length, width, height) had two compartments, three fifths for the light compartment and two fifths for the dark compartment. The compartments were connected by an entrance (9×9 cm) located on the floor. Illumination was adjusted at the center of compartments to set the light compartment to 300 lux and the dark compartment to 0-1 lux. Each individual rat was placed in the light compartment and recorded with a video camera for 5-min during exploration of the environment.

**Elevated plus-maze test**

Behavioral assay for anxiety was performed as described previously. Each rat was placed in an elevated (60 cm above floor level) plus-maze with two opposite open arms (50×10 cm each) and
two opposite closed arms (50×10 cm each) with 50 cm-high walls. Illumination was adjusted at the center of the plus maze to 200 lux. The number of entries into and the time spent on individual arms were measured for 5-min.

**Y-maze right-left discrimination task**

The task was performed as previously described with minor modifications. Y-maze with three identical arms was placed in an isolated room without a clue, and the arms were labeled A, B, and C. Animals were placed the end of one arm (40×5×20 cm; length, width, height) and recorded the number of arm entries and spontaneous alternations during an 8-min period. To assess the direction preference, the number of turns to the ipsilateral direction, infarct side in the brain hemisphere, was analyzed. The average percentage of circling behavior in the direction ipsilateral to the infarct was calculated as \[
\frac{\text{number of turn into an ipsilateral infarct}}{\text{number of total turn}} \times 100
\].

**Local field potentials recordings in vivo and analysis of neural oscillations**

Local field potentials (LFP) were recorded in the hippocampus of the rats as described previously with some modifications. The rats were anesthetized by intraperitoneal injection of urethane (1.5 g/kg) and placed in a stereotaxic frame. Glass microelectrodes (microfilament capillary 1.2 outer diameter; 5-10 MΩ) filled with artificial cerebrospinal fluid (ACSF, in mM; NaCl 126, KCl 5, CaCl₂ 2, MgCl₂ 2, NaH₂PO₄ 1.25, NaHCO₃ 26, D-glucose 10, pH 7.2) were used. The coordinates (in mm) referenced to bregma were as follows (mm to CA1): 3.8 caudal, 2.5 lateral to bregma, and 2.9 depth. LFP recordings in vivo were performed with a QP511 AC amplifier (0.1-3000 Hz bandpass; GRASS Technologies, USA) and data were digitized (5 kHz) and analyzed using Clampfit 10.2 (Axon Instruments, USA). LFP was monitored for 2-h. Analysis of the single-channel electrical traces was carried out using the Clampfit 10.2 (Axon Instruments, USA) software. To analyze changes in the normalized power of LFP, the amplitude spectrum of the normalized power was estimated by event frequency. The root
mean square (RMS) values were used to derive estimates of spectral power (mV$^2$) in the 1 Hz frequency bins for each electrode site. Spectral power values were averaged across all epochs within a single base-line, and the resulting power was expressed as mV$^2$/Hz. For each subject, fast fourier transform (FFT) of the epochs with a resolution of 0.61 Hz was computed for all the electrodes and then averaged. Non-overlapping hamming windows controlled spectral leakage. The FFT power values within each frequency between 1-50 Hz were averaged to create 50 non-overlapping < 1 Hz frequency bins, because the frequency bands of interest were defined as \( \theta \) (4-7 Hz)$^{1, 23}$. After LFP recording, renal histology and immunohistochemistry were conducted with a few animal specimens.

**Histology**

**TTC staining and measurement of infarct lesion**

To measure the infarct size following mild ischemic stroke, the brains tissue obtained from the animals after decapitation were cooled at 4℃ to harden the tissues. Six or seven coronal sections of 2 mm thickness were made from the olfactory bulb to the cerebellum. Then, each coronal section was immersed for 20-min into 2% 2,3,5-triphenyltetrazolium chloride (TTC) (Sigma-Aldrich, USA) solution at room temperature. The brain sections stained by TTC were captured using a model DP72 digital camera and DP2-BSW microscope digital camera software (Olympus, Japan), the ischemic damaged area in the infarcted hemisphere for each brain slice was measured using ImageJ (NIH, USA). Quite complete want of TTC staining was defined as core area of infarct zone$^9$. Pink colored-area in the damaged brain tissue was defined as penumbra placed periphery zone of core area, and red colored-area was defined as the undamaged normal brain tissues$^{26}$. Total infarction volume was regarded as the sum of core area and penumbra. Damaged volume was calculated as the average percentage of the hemisphere volume and adjusted for edema as described previously$^{53}$. Results are presented as the mean ±
SEM for the different animal groups. A $p$-value $<0.01$ or $<0.05$ was considered statistically significant by Bonferroni’s test.

**Tissue processing and cresyl violet staining**

Animals were transcardially perfused with phosphate buffered saline (PBS) followed by 4% paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4) under urethane anesthesia (1.5 g/kg, i.p.). The brains were removed and postfixed in the same fixative for 4-h. The brain tissues were cryoprotected by infiltration with 30% sucrose overnight. Thereafter, the entire hippocampus was frozen and sectioned with a cryostat at 30 μm and the consecutive sections were transferred into six-well plates containing PBS. For the stereological study, every sixth section in the series throughout the entire hippocampus was used in some animals. To analyze the cell death induced by MCAo, the brain slices were mounted on gelatin-coated slides and each slide was stained with cresyl violet (CV) acetate (Sigma, USA). After that, images were captured and used for the measurements of cell damage/death following mild ischemic attack using DP72 digital camera and DP2-BSW microscope digital camera software (Olympus, Japan).

**Immunofluorescence**

The immunofluorescence staining was performed as described previously with some modifications. Double immunofluorescence staining for S100 calcium-binding protein B (S100B) and Aquaporin 4 (AQP4) was performed to identify the morphological changes following mild ischemic stroke with or without sildenafil treatments in the same hippocampal tissue. The brain slices were incubated overnight at room temperature in a mixture of mouse anti-S100B IgG (diluted 1:500, Sigma, USA)/rabbit anti-AQP4 IgG (diluted 1:200, Alomone labs, Israel). After washing three times for 10-min with PBS, the slices were incubated in the mixture of Cy2- and Cy3-conjugated secondary antisera (diluted 1:200, Chemicon, USA) for 1-h at room temperature. Then, these slices were incubated in DAPI (diluted 1:500, Invitrogen, USA) as counterstaining for 15-min at room temperature. After washing with PBS, the slices
were placed on a slide and mounted with DPX (Sigma, USA). All the images were captured using a model Fluoview FV10i and FV10i software (Olympus, Japan).

**Quantification of data and statistical analysis**

Quantification and statistical analysis of each data were performed as described in the previous described study with some modifications. Optical fractionation was used to estimate the cell numbers. The technique combines optical dissection counting and fractionator sampling, and is a stereological method based on a well-designed, systematic random sampling method. By definition, the approach yields unbiased estimates of population number. Samples of deep tissue were used (optical dissector height, h, was 5 μm). Statistical analyses were performed using GraphPad Prism 7. All data obtained from the quantitative measurements were analyzed using one-way analysis of variance (ANOVA) to determine statistical significance. Bonferroni’s test was used for post-hoc comparisons. Bonferroni’s test was used for post-hoc comparisons. Statistical significance was defined as \( p < 0.05, 0.01 \) and 0.001.

**Results**

**Sildenafil treatment improved the neurological deficits following mild ischemic stroke.**

We measured the infarct size following mild ischemic stroke by performing TTC staining of brain slices from the MCAo rats and sildenafil-treated MCAo rats three days after MCAo (Fig. 1A). Although infarct lesion was clearly observed in the brain slices of MCAo30 rat models as compared with naïve controls, infarct lesion in the brains of MCAo30 rats was significantly rehabilitated by sildenafil treatment (Fig. 1B). The infarction volume in the brains for both the a MCAo30+SIL-pre \( (F_{1,9} = 18.82, P < 0.01; \text{ Fig. 1C}), \) and MCAo30+SIL-post groups \( (F_{1,8} = 60.4, P < 0.001; \text{ Fig. 1C}) \) was significantly attenuated in comparison with that of the MCAo30 rats. To further evaluate the neuronal cell death/damage in mild ischemic stroke following MCAo30, we also performed the CV staining. The CV-labelled neurons were not seen in the infarct areas
in the several brain regions, such as the striatum and the piriform cortex, of MCAo30 rats (Fig. 2B), however, these CV-positive neurons were seen in the same brain regions of the naïve controls (Fig. 2A). Notably, the CV-positive neurons were significantly enhanced both the MCAo30+SIL-pre (Fig. 2C) and MCAo30+SIL-post groups (Fig. 2D) in comparison with the MCAo30 group.

**Cerebral edema in the hippocampus induced by mild ischemic stroke was reduced by sildenafil treatment.**

To verify the functional alterations of the astrocytes sheathing the blood vessels in the hippocampus and the penumbra of MCAo30 rats, we performed double immunofluorescence labelling of S100B and AQP4 (Fig. 3). In MCAo30 rats, S100B-positive immunoreactivities in the astrocytes and vessels in the hippocampal CA1 and the penumbra region were significantly increased as compared with naïve controls (Fig. 3A and B). The number of double-labelled, S100B and AQP4, astrocytes and vessels in the CA1 ($F_{1,9} = 21.03, P < 0.01$; Fig. 3B and E) and the penumbra ($F_{1,9} = 265.3, P < 0.001$; Fig. 3B and F) were also higher in the MCAo30 rats as compared to the naïve controls. On the other hand, the number of S100B- and AQP4-positive astrocytes and vessels in the CA1 and the penumbra region of both the MCAo30+SIL-pre ($F_{1,10} = 16.98, P < 0.01$, CA1, Fig. 3C and E; $F_{1,10} = 76.17, P < 0.001$, penumbra, Fig. 3C and F) and MCAo30+SIL-post ($F_{1,10} = 10.63, P < 0.01$, CA1, Fig. 3D and E; $F_{1,10} = 35.24, P < 0.001$, penumbra, Fig. 3D and F) was significantly reduced in comparison with that of the MCAo30 rats. However, double-labelled, S100B and AQP4, immunofluorescences in the hippocampal CA1 area of the MCAo30+SIL-pre group were down-regulated to the level of naïve controls ($F_{1,9} = 7.20, P = 0.19$; Fig. 3C and E).

**Anxiogenic disorder induced by mild ischemic stroke was alleviated by sildenafil treatment.**
To examine whether sildenafil treatment alleviates anxiety disorder induced by MCAo30, we analyzed levels of anxiety-related behaviors of the MCAo rats and sildenafil-treated MCAo rats by performing elevated plus-maze and light/dark transition task (Fig. 4B and C). Anxiety-related behavior tests that may cause stress in the animals were conducted after open-field test and Y-maze test were performed (Fig. 4A). In the elevated plus-maze task, MCAo30 rats made fewer entries into the aversive open arms as compared to the naïve controls ($F_{1,11} = 9.85, P < 0.01$; Fig. 4B-1). Especially, MCAo30+SIL-post group showed normal anxiety-like behavior, similar to the level of naïve rats ($F_{1,10} = 7.31, P < 0.05$, MCAo30+SIL-post vs MCAo30; Fig. 4B-1), however, MCAo30+SIL-pre group did not show improvement of MCAo30 induced anxiogenic behavior ($F_{1,11} = 8.01, P < 0.05$, MCAo30+SIL-pre vs Naïve; Fig. 4B-1). The total number of entries into both, open and closed, arms of the MCAo30 rats was decreased in comparison with naïve controls ($F_{1,11} = 10.72, P < 0.01$; Fig. 4B-2). Notably, these deficits in locomotion was improved in the both MCAo30+SIL-pre ($F_{1,11} = 12.57, P < 0.01$, MCAo30+SIL-pre vs MCAo30; Fig. 4B-2) and MCAo30+SIL-post groups ($F_{1,11} = 5.72, P < 0.05$, MCAo30+SIL-post vs MCAo30; Fig. 4B-2), to a level similar to that of the naïve controls ($F_{1,14} = 0.04, P = 0.84$, MCAo30+SIL-pre vs Naïve; $F_{1,12} = 0.57, P = 0.46$, MCAo30+SIL-post vs Naïve; Fig. 4B-2). In the light-dark transition test, the time that the MCAo30 rat spent in the light chamber was significantly shorter than that of the naïve controls ($F_{1,11} = 205.6, P < 0.001$, MCAo30 vs Naïve; Fig. 4C-1). Consistently, MCAo30 rats made fewer transitions from the dark to the light compartment than the naïve controls ($F_{1,11} = 5.56, P < 0.05$, MCAo30 vs Naïve; Fig. 4C-2). Duration in the light compartment was increased in the MCAo30+SIL-pre ($F_{1,11} = 21.47, P < 0.001$, MCAo30+SIL-post vs MCAo30; Fig. 4C-1) and MCAo30+SIL-post ($F_{1,11} = 10.22, P < 0.01$, MCAo30+SIL-post vs MCAo30; Fig. 4C-1) groups in comparison with the MCAo30 rats. Furthermore, the MCAo30+SIL-post group showed alleviated anxious behavior, to a level similar to that of the naïve control ($F_{1,11} = 1.78, P = 0.20$, MCAo30+SIL-post vs Naïve; Fig. 4C-2). There was high correlation between the infarct size and anxiogenic behavior.
(Pearson correlation coefficient $r = -0.8392$, $p < 0.01$, Fig. 4B-3; $r = -0.86914$, $p < 0.01$, Fig. 4C-3). Together, our findings demonstrate that sildenafil treatment attenuates anxiogenic behavior induced by mild ischemic stroke following MCAo in rats.

**Deficits in locomotion and movement associated with MCAo were improved by sildenafil treatment.**

In the open-field assay, MCAo30 rats showed deficits in locomotor activity in comparison with the naïve controls ($F_{1,24} = 47.67$, $P < 0.001$, MCAo30 vs Naïve; Fig. 5A-1 and 2). Total distance moved in the open-field arena was increased in both the MCAo30+SIL-pre ($F_{1,13} = 29.18$, $P < 0.001$, MCAo30+SIL-pre vs MCAo30, Fig. 5A-2) and the MCAo30+SIL-post ($F_{1,15} = 6.6$, $P < 0.05$, MCAo30+SIL-post vs MCAo30; Fig. 5A-2) groups in comparison with MCAo30 rats. In addition, MCAo30 rat models showed left rotation behavior, and the number of ipsilateral circling turns was increased in comparison with naïve controls ($F_{1,10} = 20.56$, $P < 0.01$, MCAo30 vs Naïve; Fig. 5A-3). Interestingly, we observed that these motor defects were ameliorated by sildenafil treatment ($F_{1,10} = 18.09$, $P < 0.01$, MCAo30+SIL-pre vs MCAo30; $F_{1,10} = 20.13$, $P < 0.01$, MCAo30+SIL-post vs MCAo30; Fig. 5A-3) and found a correlation coefficient between infarct size and movement disorder (Pearson correlation coefficient $r = -0.92008$, $p < 0.001$, Fig. 5A-4).

Furthermore, we noticed that the MCAo30 rats showed preference for left direction in the Y-maze (Fig. 5B-1). We measured direction preference in the Y-maze task as described previously, and confirmed that the MCAo30 rats showed higher preference for left direction, ipsilateral side of the MCAo30 in the left hemisphere of the brain, than naïve controls ($F_{1,17} = 133.59$, $P < 0.001$, MCAo30 vs Naïve; Fig. 5B-2). We also found that the direction preference induced by MCAo could be improved by sildenafil treatment ($F_{1,15} = 13.46$, $P < 0.01$, MCAo30+SIL-pre vs MCAo30; $F_{1,13} = 78.51$, $P < 0.001$, MCAo30+SIL-post vs MCAo30; Fig. 5B-2), with the MCAo30+SIL-post group showing a normal level of direction preference in comparison with
 naïve controls ($F_{1,14} = 2.13, P = 0.16, \text{MCAo30+SIL-post vs Naïve}; \text{Fig. 5B-2})$. Thus, our findings indicate that sildenafil treatment alleviates deficits of locomotion and direction preference induced by mild ischemic stroke following MCAo in rats.

**Alteration of theta-frequency oscillations induced by mild ischemic stroke was alleviated by sildenafil treatment.**

To examine 1) whether alteration of neural oscillations at 4-7 Hz, associated with anxiety disorder\(^1,^{23,49,59}\), can be induced by MCAo, if so, 2) whether altered theta-frequency oscillations can be recovered by sildenafil treatment, we performed LFP recordings in the hippocampal CA1 region of MCAo30 rats and sildenafil-treated MCAo30 rats under urethane anesthesia (1.5 g/kg, i.p.) (Fig. 6A and B). Power spectral analysis showed that power of theta-frequency oscillations was significantly increased in the MCAo30 in comparison with that of the naïve controls ($F_{1,8} = 8.78, P < 0.05, \text{MCAo30 vs Naïve}; \text{Fig. 6C}$). Importantly, sildenafil treatment alleviated theta power to a level similar to that of the naïve rats ($F_{1,8} = 33.25, P < 0.001, \text{MCAo30+SIL-pre vs MCAo30}; F_{1,8} = 16.77, P < 0.01, \text{MCAo30+SIL-post vs MCAo30}; \text{Fig. 6C}$). Normalized LFP power of MCAo30+SIL-pre group was decreased to the level of naïve controls ($F_{1,8} = 2.59, P = 0.14, \text{MCAo30+SIL-pre vs Naïve}; F_{1,8} = 12.32, P < 0.05, \text{MCAo30+SIL-pre vs MCAo30}; \text{Fig. 6D}$), however, the level in MCAo30+SIL-post group was higher than that of the naïve group (MCAo30, $F_{1,8} = 8.28, P < 0.05$; MCAo30+SIL-post, $F_{1,8} = 5.21, p < 0.001$; Figure 6D). Together, these results indicate that sildenafil treatment alleviates alteration of theta-frequency oscillations, a neural oscillatory marker for anxiety disorder, induced by mild ischemic stroke in rats.

**Discussions**

In this study, we investigated the therapeutic effect of sildenafil on anxiogenic behavior and movement disorder induced by mild ischemic stroke in rats and demonstrated the use of PDE5i
as a novel therapeutic approach for the improvement of cerebral blood flow in the infarct region in the brain.

Consistent with a previous study, a large infarct area, likely an edema lesion, was observed in the striatum and the piriform cortex following mild stroke (Fig. 1B and 2B)\textsuperscript{52}. In addition, neuronal population labelled by CV were not observable in this infarcted region of the brain. Recent studies in rodents also suggested that treatment with PDE5i increased cerebral blood flow, and improved brain edema, infarct volume, neuronal damage, and neurological function after ischemic stroke\textsuperscript{14, 75, 76}. PDE5i was effective in increasing levels of synaptophysin, brain derived neurotrophic factor (BDNF)/tropomyosin-related kinase B (TrkB), nerve growth factor (NGF)/tropomyosin-related kinase A (TrkA), and postsynaptic density protein 95 (PSD-95)/neuronal nitric oxide synthases (NOS)\textsuperscript{14}. Furthermore, PDE5i prevented neurotoxicity induced by reactive oxygen species (ROS), and has been regarded as a possible therapeutic tool for the brain edema, inflammation and neuronal damage in the central nervous system\textsuperscript{45}. Here we found that infarction volume induced by mild ischemic stroke was significantly reduced in the brains of both the MCAo30+SIL-pre- and MCAo30+SIL-post groups (Fig. 1 and 2).

Sildenafil inhibits cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and increases cGMP, its effect is similar to the upregulation of nitric oxide (NO)\textsuperscript{31}. Enhancing NO-cGMP signaling by sildenafil increases blood flow and has neuroprotective effects in the rat model of hypoxic–ischemic brain injury\textsuperscript{13}. Furthermore, upregulation of cGMP signaling by sildenafil activates cGMP-dependent protein kinase (PKG) leading to decreased levels of intracellular calcium ions\textsuperscript{3, 18}. Ca\textsuperscript{2+} ions play a vital role as a major initiator and activator in the ischemic cell death pathways\textsuperscript{15}. Elevated levels of intracellular Ca\textsuperscript{2+} ions in serum plays a role in decrease of infarct volume and outcome in ischemic stroke patients\textsuperscript{11, 12, 48}. Ca\textsuperscript{2+} accumulation triggers mitochondrial damage and contributes to delayed neuronal death as well as reactive oxygen species (ROS)\textsuperscript{15, 40}. Especially, reducing level of Ca\textsuperscript{2+} by sildenafil in the mitochondria plays a protective role in the neuronal cells of hippocampus\textsuperscript{5, 61}. These results
indicate that downregulation of mitochondrial calcium signaling caused by sildenafil treatment may contribute to reducing infarction volume induced by mild ischemic stroke.

Previously, diverse outcomes of sildenafil treatment in the myocardial infarct size of rabbits have been shown, and these results were influenced by dosage, difference of sildenafil treatment time after stroke. In our present study, MCAo30+SIL-post-treatment were more effective on damage following mild ischemic stroke than MCAo30+SIL-pre-treatment. Anti-inflammatory effects of sildenafil provide protection against lesion extension following treatment of sildenafil after surgical in permanent MCAo of neonatal mice. These results may suggest that sildenafil is beneficial for the therapy of mild ischemic stroke patients. Sildenafil evokes neurogenesis and reduces neurological deficits through increased levels of cGMP dependent on the activation of the mitogen-activated protein kinase (MAPK). Increasing of neural stem cells proliferation by cGMP enhanced neurogenesis, and these may result from decreasing of infarction volume by ischemia. Enhancement of neurogenesis may contribute to functional recovery after sildenafil treatment. For more information, biochemical and pharmacological experiments are required to reveal the efficacy of sildenafil in this process.

Increased S100B expression was observed in blood vessels and astrocytes, as swelling form of cell body, in the hippocampus following MCAo (Fig. 3). Previously, upregulation of S100B, glial fibrillary acidic protein (GFAP), and neuron specific enolase (NSE) in the blood of patients with stroke, brain trauma, and hypoxic encephalopathy were reported. S100B is involved in regulating the calcium influxes caused by the reaction of astrocytes to injury, and stimulating astrocytic proliferation via interaction with the transcription factors. In the present study, we observed that S100B expression was decreased in the hippocampal CA1 and the penumbra of both MCAo30+SIL-pre and MCAo30+SIL-post indicating neuroprotective efficacies and the novelty of sildenafil as a therapeutic agent (Fig. 3). AQP4 regulates extracellular matrix volume, potassium buffering, cerebrospinal fluid circulation, neuro-inflammation, osmosensation, and calcium signaling. It has been detected in the astrocytic
end-feet, and encapsulates the blood vessels in a similar way as S100B\textsuperscript{4, 46, 70}. AQP4 expression was enhanced at 30-min after permanent MCAo\textsuperscript{38}. However, other studies reported downregulation, and sudden loss of AQP4, and sudden loss of the AQP4 in astrocytic end-feet following transient ischemia in regions of vascular damage of the post-ischemic phase\textsuperscript{21, 22, 62}. These discrepancies may result from the varying severity of ischemic stroke. In the present study, markedly suppressed co-expression of AQP4 and S100B in the astrocytic structures of the MCAo\textsubscript{30}+SIL-pre and MCAo\textsubscript{30}+SIL-post (Fig. 3) indicate that treatment with sildenafil effectively improve brain infarction induced by MCAo, and can be regarded as a neuroprotective reagent. These results further strengthen the previous reports on the neuroprotective effects of sildenafil. In addition, our findings support the reports that S100B down-regulation after treatment with sildenafil is involved in the anti-inflammation process through the inhibition of astrogliosis, and that the brain damage induced by stroke may be related to functional alteration of AQP4 and S100B after mild ischemic stroke. However, further studies are needed to confirm this hypothesis.

Based on our findings, anxiety disorder (Fig. 4) and locomotion deficits (Fig. 5) in MCAo\textsubscript{30} rats were significantly reduced with sildenafil therapy. Previous studies showed that NO-cGMP pathway is associated with anxious behaviors, although there are also arguments of the neural mechanism underlying these findings\textsuperscript{20, 25, 37, 68, 69}. In the present study, sildenafil treatment improved anxiogenic behavior induced by mild ischemic stroke in the elevated plus maze and light-dark transition test (Fig. 4A-1 and 4B-1). In addition, the MCAo in rats caused hypolocomotion and stereotypic events with expected simultaneous enhancement in resting duration following mild ischemic stroke\textsuperscript{73}. cGMP upregulation promotes the proliferation of motor neurons. Both PDE5i and 8q-cGMP, an analogue of cGMP, provided neuroprotection against neurotoxicity induced by ROS\textsuperscript{45}. Similarly, the results of our behavioral experiments showed marked improvement in locomotion deficits of both the MCAo\textsubscript{30}+SIL-pre and the MCAo\textsubscript{30}+SIL-post groups (Fig. 5A-1 and 2). A spontaneous alteration assay using Y-maze task
has been used for measuring working memory, like short-term memory in a new environment, in rodents\textsuperscript{56}. However, contrary to the objectives of the experiment, the MCAo rat models showed a preference for the left direction, the ipsilateral side of MCAo in the left hemisphere of the brain, in the open-field and Y-maze test (Fig. 5). Notably, preference for the left direction of the MCAo30 rats in the Y-maze test was alleviated by sildenafil treatment (Fig. 5B-2), and the MCAo30+SIL-post group showed a normal level of direction preference similar to that of the naïve controls (Fig. 5B-2). Thus, our findings indicate that motor deficits following mild ischemic stroke in rats can be improved by sildenafil treatment.

Altered theta-frequency oscillations in the hippocampus are associated with anxiety disorder in rodents\textsuperscript{1, 49, 59}. Enhanced hippocampal theta rhythm was observed during fear responses and anxiogenic states, supporting the involvement of hippocampal theta rhythm in the anxiety\textsuperscript{1, 2, 28, 29}. Based on our anxiety-related behavioral assays, sildenafil treatment alleviated alteration of theta-frequency oscillations induced by MCAo30 (Fig. 6). These findings suggest a possible role of sildenafil, a selective PDE5i, in the improvement of theta signal and phenotype anxiety and therefore improvement of anxiety disorder and movement deficits induced by mild ischemic stroke in rats.

**Conclusion**

Our findings in the present study suggest sildenafil as an effective pharmacological agent for preventing neuronal damage in the brain. In addition, our study extends the definitive knowledge of diverse phenotypical sequela and functional complications of mild ischemic stroke, and provides preclinical evidence for PDE5i efficacy in anxiety and movement disorders as well as other residue disorders induced by mild ischemic stroke. But, when applying the results of animal experiments to humans, should be considered to a lot of variables that dosage, frequency and way. As well, these hypotheses about enhancing mitochondrial death, neurogenesis by cGMP and functional alteration of AQP4 and S100B by sildenafil is required definitive knowledge about pathophysiology mechanisms.
CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

INFORMED CONSENT

This type of study does not require informed consent.

AUTHOR CONTRIBUTIONS

Conceptualization : YHY, SWK, JK, JSO, DSK
Data curation : YHY, SWK, JK
Formal analysis : YS, HI, SJK, DYY
Funding acquisition : JSO, DSK
Methodology : MRL, DKP
Project administration : JSO, DSK
Visualization : YHY, SWK, JK
Writing - original draft : YHY, SWK, JK, JSO, DSK
Writing - review & editing : YHY, SWK, JK, YS, HI, SJK, DYY, MRL, DKP, JSO, DSK

ORCID

Yeon Hee Yu: https://orcid.org/0000-0003-4852-6151
Seong-Wook Kim: https://orcid.org/0000-0002-8928-290X
Juhyeon Kang: https://orcid.org/0000-0002-6773-0353
Yejin Song: https://orcid.org/0000-0002-5908-9244
Hyuna Im: http://orcid.org/0000-0002-0155-6460
Seo Jeong Kim: https://orcid.org/0000-0002-4235-6748
Dae Young Yoo: http://orcid.org/0000-0002-0278-2291
Man-Ryul Lee: https://orcid.org/0000-0002-2351-9679
Dae-Kyoon Park: https://orcid.org/0000-0003-0147-2424
Jae Sang Oh: https://orcid.org/0000-0003-4570-6769
Duk-Soo Kim: https://orcid.org/0000-0003-2956-3942

• Acknowledgements

This work was supported by the Soonchunhyang University and a Basic Science Research Program (NRF-2017R1D1A1B05036195 & NRF-2020R1F1A1066362) through the National Research Foundation of Korea funded by the Ministry of Science.

References


49. Padilla-Coreano N, Bolkan SS, Pierce GM, Blackman DR, Hardin WD, Garcia-Garcia...


28


Figure legends

**Figure 1. Sildenafil treatment reduced the infarction volume induced by mild ischemic stroke.**

(A) Representative diagram showing the overall surgical groups and histology time schedules.

(B) Brain slices showing major infarct zones in the brains of MCAo30 rats. The infarct size in the brains of both the MCAo30+SIL-pre and the MCAo30+SIL-post groups were significantly reduced, as compared with MCAo30 rat and to a level similar to the naïve controls. White areas indicate infarct zones in the brain tissue after mild ischemic stroke; red areas indicate intact tissues; a dotted line indicates the core area of infarct zone. (C) Quantitative analysis of the infarct size using TTC staining. Data were presented as the mean ± SEM. **P < 0.01, ***P < 0.001; one-way ANOVA.
Figure 2. Neuroprotective effect of sildenafil on the infarction induced by mild ischemic stroke.

CV labeling in the ipsilateral side of the striatum and piriform cortex of (A) the naïve controls, (B) the MCAo30, (C) the MCAo30+SIL-pre, and (D) the MCAo30+SIL-post rat models. Rectangles in panels A, B, C and D indicate the high-magnification of panels A1 and 2, B1 and 2, C1 and 2, and D1 and 22, respectively. Arrows in panels C1, C2, D1 and D2 indicate the CV-positive neuronal cell body. Scale bar = 280 μm (panels A, B, C and D), 50 μm (panels A1 and 2, B1 and 2, C1 and 2, and D1 and 2).
Figure 3. Sildenafil treatment reduced cerebral edema in the hippocampus induced by mild ischemic stroke.

Double labelling of S100B and AQP4 in the hippocampus and the penumbra of (A) the naïve controls, (B) the MCAo30, (C) the MCAo30+SIL-pre, and (D) the MCAo30+SIL-post rat models. S100B (green); AQP4 (red); Merged images (yellow). Scale bar = 18.8 μm. A.U., arbitrary unit. Data are presented as the mean ± SEM. # $P < 0.05$, ## $P < 0.01$, ### $P < 0.001$, compared with the naïve controls; ** $P < 0.01$, *** $P < 0.001$, compared with the MCAo30 group; one-way ANOVA.
Figure 4. Sildenafil treatment alleviated anxiogenic behavior induced by mild ischemic stroke.

(A) Representative diagram showing the overall surgical groups and timeline of experiment. (B) Elevated plus-maze task. Percentage of entries into the open arms (B-1) and total number of entries into the open and closed arms of the naïve controls, the MCAo30, the MCAo30+SIL-pre, and the MCAo30+SIL-post groups (B-2). Scatter plots shows correlation between the MCAo infarct size and anxiogenic behavior about elevated plus-maze (B-3). (C) Light/dark transition task. The total time in the light box (C-1) and number of light/dark transition were validated in the naïve controls, the MCAo30, the MCAo30+SIL-pre, and the MCAo30+SIL-post groups (C-2). Scatter plots shows correlation between the MCAo infarct size and anxiety about light/dark box (B-3). Data are presented as the mean ± SEM. # P < 0.05, ## P < 0.01, ### P < 0.001, compared with the naïve controls; * p < 0.05, ** p < 0.01, *** p < 0.001, compared with the MCAo30 group. + P < 0.05, a comparison between the MCAo30+SIL-pre and the MCAo30+SIL-post; one-way ANOVA.
Figure 5. Sildenafil treatment improved locomotion deficits and directional preference accompanying mild ischemic stroke.

(A) Open-field test. Representative cumulative traces of navigation pathways of naïve controls, the MCAo30, the MCAo30+SIL-pre, and the MCAo30+SIL-post groups during exploratory behavior in the open-field arena (A-1). Total distance moved in the open-field arena of naïve controls, the MCAo30, the MCAo30+SIL-pre, and the MCAo30+SIL-post groups (A-2). Circling behavior in the open-field arena of naïve controls, the MCAo30, the MCAo30+SIL-pre, and the MCAo30+SIL-post groups (A-3). Graph shows correlation between the MCAo infarct size and movement disorders (A-4).

(B) Y-maze test. The schematic diagram showing the MCAo rat model’s preference for left direction, ipsilateral side of MCAo in the left hemisphere of the brain, in the Y-maze (B-1). The averaged percentage of preference for left direction in the naïve controls, the MCAo30, the MCAo30+SIL-pre, and the MCAo30+SIL-post (B-2). Data are presented as the mean ± SEM. ### $P < 0.001$, compared with the naïve controls; ** $P < 0.01$, *** $P < 0.001$, compared with the MCAo30 group; ++ $P < 0.01$, comparison between the MCAo30+SIL-pre and the MCAo30+SIL-post; one-way ANOVA.
Figure 6. Sildenafil treatment alleviated the alteration of theta-frequency oscillations induced by mild ischemic stroke.

(A) Representative raw traces of LFP recordings in the CA1 region of the hippocampus during urethane-induced anesthesia. (B) Power spectral analysis of LFP in the CA1 region of naïve controls, the MCAo30, the MCAo30+SIL-pre, and the MCAo30+SIL-post groups. (C and D) Power spectral analysis of 4-7 Hz neural oscillations in the hippocampal CA1 region (C) and normalized total power (D) of naïve controls, the MCAo30, the MCAo30+SIL-pre, and the MCAo30+SIL-post rat models. Data are presented as the mean ± SEM. \(^{\#} P < 0.05, ^{\#\#} P < 0.001, ^{\#\#\#} P < 0.001,^{**} P < 0.01, ^{***} P < 0.001, ^{\ddagger\ddagger} P < 0.01, ^{\ddagger\ddagger\ddagger} P < 0.001,^{\ddagger\ddagger\ddagger\ddagger} P < 0.0001,\) compared with the naïve controls; \(^{**} P < 0.01, ^{***} P < 0.001, \) compared with the MCAo30 group; \(^{\ddagger\ddagger} P < 0.01, \) comparison between the MCAo30+SIL-pre and the MCAo30+SIL-post; one-way ANOVA.